financetom
Business
financetom
/
Business
/
Humana Q1 Adjusted Earnings, Revenue Rise; 2025 Adjusted EPS Outlook Affirmed
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Humana Q1 Adjusted Earnings, Revenue Rise; 2025 Adjusted EPS Outlook Affirmed
May 25, 2025 9:35 PM

06:15 AM EDT, 04/30/2025 (MT Newswires) -- Humana (HUM) reported Q1 adjusted earnings Wednesday of $11.58 per diluted share, up from $7.23 a year earlier.

Analysts polled by FactSet expected $10.07.

Revenue for the quarter ended March 31 was $32.11 billion compared with $29.61 billion a year earlier.

Analysts surveyed by FactSet expected $32.2 billion.

The company affirmed its 2025 adjusted EPS guidance of about $16.25. Analysts surveyed by FactSet expect $16.33.

Humana shares were up 4.9% in recent premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Vanda Pharmaceuticals' Shares Rally After Company Receives $466 Million Buyout Offer From Cycle Pharma
Vanda Pharmaceuticals' Shares Rally After Company Receives $466 Million Buyout Offer From Cycle Pharma
Jun 6, 2024
10:00 AM EDT, 06/06/2024 (MT Newswires) -- Vanda Pharmaceuticals' ( VNDA ) shares were surging in early Thursday trading, rising nearly 25%, after saying it received an unsolicited and non-binding indication of interest from privately held Cycle Group Holdings, the parent company of Cycle Pharmaceuticals, offering to buy all of Vanda's outstanding shares for $8 per share. The total cash...
FDA Selects Moderna's Rare Disease Candidate For Accelerated Development Program
FDA Selects Moderna's Rare Disease Candidate For Accelerated Development Program
Jun 6, 2024
Thursday, the FDA selected Moderna Inc’s mRNA-3705 for the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program. mRNA-3705 is an investigational therapeutic for methylmalonic acidemia (MMA) due to methylmalonic-CoA mutase (MUT) deficiency. “Selection for this program will enable enhanced communication with the U.S. FDA, resulting in acceleration of our development program as we prepare for pivotal study...
-- ThreeD Capital Inc. Brief: Up 40% After Announcing Settlement of Litigations With New Found Gold Corp and Palisades and  Collin Kettell
-- ThreeD Capital Inc. Brief: Up 40% After Announcing Settlement of Litigations With New Found Gold Corp and Palisades and Collin Kettell
Jun 6, 2024
09:45 AM EDT, 06/06/2024 (MT Newswires) -- Price: 0.40, Change: +0.12, Percent Change: +41.07 ...
Buffett's NetJets sues pilots' union for defamation over safety, training claims
Buffett's NetJets sues pilots' union for defamation over safety, training claims
Jun 6, 2024
June 5 (Reuters) - NetJets, the luxury plane unit of billionaire Warren Buffett's Berkshire Hathaway Inc ( BRK/A ), sued its 3,400-member pilots union for defamation over statements about its commitment to safety and training pilots. The lawsuit filed in a state court in Columbus, Ohio, where NetJets is based, seeks unspecified damages, and follows years of often contentious relations...
Copyright 2023-2026 - www.financetom.com All Rights Reserved